Episode 38 – IV Iron and SGLT2 Inhibitors in Heart Failure (Repeat)

Welcome back Rounds Table Listeners!

We are back with an oldie but a goodie!

In this repeat episode, Drs. Mike and John Fralick do a Rapid Fire session to discuss two papers exploring heart failure – specifically, if intravenous iron or the initiation of SGLT2 inhibitors in hospital for patients with heart failure improves clinical outcomes. Two papers, here we go!

1. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial (0:00 – 7:18).

2. The SLGT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial (7:18 – 16:31).

And for the Good Stuff:

• Canadian men qualify for first World Cup since 1986 with shutout victory on home soil (16:31 – 17:18).
• SGLT2rx.com (A tool designed to help providers understand the benefits and risks of SGLT2 inhibitors for patients with and without diabetes; 17:18 – 18:12). 

Questions? Comments? Feedback? We’d love to hear from you! @roundstable